SCHEMBL17883261

SCHEMBL17883261

COCCNC(=O)c1cn(-c2ccccc2)nn1

nearest known ligand 0.63

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
RIPK1 Q13546 1/20 0.63
ACKR3 P25106 3/20 0.54
MIF P14174 3/20 0.53
CYP2C19 P33261 1/20 0.51
HPGD P15428 3/20 0.50
ALDH1A1 P00352 2/20 0.50
DRD2 P14416 1/20 0.48
DRD4 P21917 1/20 0.48
DRD3 P35462 1/20 0.48
GLS O94925 1/20 0.48
ESRRA P11474 1/20 0.47
MAPK1 P28482 1/20 0.46
ADORA2A P29274 1/20 0.46
ADORA1 P30542 1/20 0.46
KDM4E B2RXH2 1/20 0.46
LMNA P02545 1/20 0.46
GLA P06280 1/20 0.46
GAA P10253 1/20 0.46
MAPT P10636 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17883296 0.84 RIPK1 (0.63) RIPK1ACKR3MIFESRRAGLA
SCHEMBL30009481 0.82 RIPK1 (0.63) RIPK1ACKR3MIFDRD2DRD4
SCHEMBL73126 0.81 RIPK1 (0.62) RIPK1ACKR3MIFALDH1A1ESRRA
SCHEMBL12571591 0.79 CA12 (0.66) RIPK1ESRRAKDM4EGAAMAPT
SCHEMBL17883253 0.77 RIPK1 (0.58) RIPK1ACKR3MIFESRRA
SCHEMBL21635351 0.76 RIPK1 (0.56) RIPK1ACKR3MIFDRD2DRD4
SCHEMBL28542983 0.76 RIPK1 (0.56) RIPK1ACKR3MIFDRD2DRD4
SCHEMBL12522014 0.74 MIF (0.77) RIPK1ACKR3MIFALDH1A1LMNA
SCHEMBL23525601 0.74 RIPK1 (0.46) RIPK1ACKR3MIFDRD2DRD4
SCHEMBL23889183 0.74 ESRRA (0.59) RIPK1MIFESRRAGLA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10738011-B2 Derivatives of 5-(hetero)arylpyrazol-3-carboxylic amide or 1-(hetero)aryltriazol-4-carboxylic amide useful for the treatment of inter alia cystic fibrosis PROTEOSTASIS THERAPEUTICS, INC. (US) 2020-08-11 US disclosed
WO-2016105484-A1 DERIVATIVES OF 5-(HETERO)ARYLPYRAZOL-3-CARBOXYLIC AMIDE OR 1-(HETERO)ARYLTRIAZOL-4-CARBOXYLIC AMIDE USEFUL FOR THE TREATMENT OF INTER ALIA CYSTIC FIBROSIS PROTEOSTASIS THERAPEUTICS, INC. (US) 2016-06-30 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10738011-B2 Derivatives of 5-(hetero)arylpyrazol-3-carboxylic amide or 1-(hetero)aryltriazol-4-carboxylic amide useful for the treatment of inter alia cystic fibrosis CFTR, SLC33A1, SLC26A4 RIPK1 2731/4885ACKR3 1560/4885MIF 4153/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.